Fluicell

Fluicell Net Change in Cash

The Net Change in Cash of Fluicell (FLUI.ST) as of Nov 20, 2026 is -13.66 M SEK. In the previous year, Net Change in Cash was 13.16 M SEK — a change of -203.81% (lower).

Net Change in Cash

-13.66 MSEK

YoY

-203.81%

Last updated:

Net Change in Cash of Fluicell is 2025 -13.66 M SEK. Net Change in Cash of Fluicell was 2024 13.16 M SEK. It decreases by -203.81% lower compared to the previous year.

The Fluicell Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
14.40 M SEK
Jan 1, 2019
-13.79 M SEK
Jan 1, 2020
10.36 M SEK
Jan 1, 2021
1.89 M SEK
Jan 1, 2022
3.76 M SEK
Jan 1, 2023
-21.69 M SEK
Jan 1, 2024
13.16 M SEK
Jan 1, 2025
-13.66 M SEK
The Fluicell Net Change in Cash history
YEARNet Change in CashYoY
-13.66 MSEK-203.81%
13.16 MSEK-160.67%
-21.69 MSEK-676.51%
3.76 MSEK+98.68%
1.89 MSEK-81.72%
10.36 MSEK-175.13%
-13.79 MSEK-195.80%
14.40 MSEK+113.81%
6.73 MSEK+1,807.65%
353,000.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Net Change in Cash of Fluicell is -13.66 M SEK in 2025.

Net Change in Cash of Fluicell changed from 13.16 M SEK to -13.66 M SEK, representing a -203.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Fluicell since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Fluicell

All Key Metrics — Fluicell